Which clinical feature best distinguishes acute severe asthma exacerbation from acute anaphylaxis presenting with bronchospasm in a 28-year-old woman?

Explanation

## Distinguishing Acute Severe Asthma from Anaphylaxis with Bronchospasm ### Key Discriminating Features **Key Point:** The presence of **urticaria and angioedema** is the single best clinical feature that distinguishes anaphylaxis (presenting with bronchospasm) from acute severe asthma exacerbation. These cutaneous/mucosal manifestations are present in ~90% of anaphylaxis cases and are virtually absent in pure asthma exacerbations. ### Comparative Table | Feature | Acute Severe Asthma | Anaphylaxis with Bronchospasm | |---------|--------------------|---------------------------------| | **Onset** | Gradual (hours to days) | Sudden (minutes after allergen exposure) | | **Skin/mucosal findings** | Absent | Urticaria, angioedema (~90% of cases) | | **Bronchospasm reversibility** | Rapid response to SABA (15–20 min) | Poor/delayed response to SABA; requires epinephrine | | **Hemodynamic instability** | Rare (only in extremis) | Common (hypotension, tachycardia) | | **GI symptoms** | Absent | Nausea, vomiting, cramping | | **First-line treatment** | SABA ± systemic corticosteroids | Intramuscular epinephrine | ### Why Urticaria and Angioedema is the Best Discriminator **High-Yield:** The question asks for the feature that **best distinguishes** the two conditions in a clinical scenario. While peak flow reversibility (Option A) is a hallmark of asthma physiology, it is a **functional/investigative** parameter that takes time to assess and is not a bedside clinical feature that immediately separates the two diagnoses. In contrast, **urticaria and angioedema are pathognomonic clinical signs of anaphylaxis** — their presence immediately points away from asthma and toward anaphylaxis, triggering the correct first-line treatment (epinephrine). **Clinical Pearl:** According to the World Allergy Organization (WAO) and Harrison's Principles of Internal Medicine (21e, Ch. 380), anaphylaxis is highly likely when skin/mucosal involvement (urticaria, flushing, angioedema) accompanies acute respiratory compromise. Asthma exacerbations, even severe ones, do not produce urticaria or angioedema. ### Why Other Options Are Less Discriminating - **Option A (Peak flow reversibility):** A valid asthma marker but requires spirometry/peak flow meter and time; not a single bedside clinical feature that immediately distinguishes the two. - **Option B (Ability to speak in full sentences):** Reflects severity of airflow obstruction but is non-specific — both severe asthma and severe anaphylaxis can impair speech. - **Option C (Hypotension and tachycardia):** More characteristic of anaphylaxis, but can occur in extremis in severe asthma; less specific than urticaria/angioedema. ### Mechanism Anaphylaxis involves systemic IgE-mediated mast cell and basophil degranulation, releasing histamine, tryptase, and leukotrienes. Histamine acting on H1 receptors in dermal vessels produces urticaria and angioedema — a hallmark absent in asthma, where bronchospasm is the primary manifestation without systemic mast cell activation at the skin level. [cite:Harrison 21e Ch 380; WAO Anaphylaxis Guidelines 2020]